FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1508516210> ?p ?o ?g. }

• W1508516210 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAMetastatic clear cell renal cell carcinoma (ccRCC) disease is responsible for significant morbidity and represents the main cause of death in patients with advanced ccRCC. We have developed a novel dendritic cell based vaccine targeting human carbonic anhydrase IX (hCAIX; DC-Ad-GM·CAIX) and compared it with the ccRCC standard-of-care drug, sunitinib as a monotherapy and in simultaneous vaccine-sunitinib combination therapy.Immunocompetent mice (Balb/c) were orthotopically-transplanted with syngeneic RCC-hCAIXpositive (NPR-IX) tumor cells, immunized, and/or treated with sunitinib at low-dose (5mg/kg/d), high-dose (40mg/kg/d) or untreated. At termination, primary tumor size (weight), lung metastatic burden, hCAIX and immune-markers expression levels were compared.Mono-immunotherapy with DC-Ad-GM·CAIX vaccine suppressed metastatic tumor growth: the total number of metastatic heterotypic foci (i.e., hCAIX positive and negative foci) following vaccination decreased 2.5 fold compared with untreated mice (P 10 fold). Vaccination alone resulted in reduced primary tumor burden of RCC-hCAIXpositive cells to <25% of the tumor cell population, with the remaining cells lacking hCAIX expression (hCAIXnegative); there was no significant overall primary tumor reduction compared to untreated mice. In contrast, sunitinib, whether given as high-dose monotherapy or in combination with the vaccine, inhibited the primary orthotopic tumors, achieving 35% (P=0.0001) and 51% (P=1.7e-7) tumor reduction, respectively. However, sunitinib monotherapy was less effective in reducing the metastatic tumor burden compared with the vaccine.In fact, simultaneous administration of vaccine and sunitinib increased the metastatic tumor burden in heterotypic tumors composed also of hCAIXnegative cells.In conclusion, this preclinical study demonstrates that (i) the DC-Ad-GM·CAIX vaccine effectively controls both primary and metastatic hCAIXpositive tumors and forms the basis for a phase I trial in metastatic ccRCC patients, which has been initiated at UCLA (http://clinicaltrials.gov number [NCT01826877][1]), (ii) Antigen editing with loss of hCAIX is an important immune escape mechanism, (iii) This in vivo study raises caution regarding the use of DC-Ad-GM·CAIX vaccine in simultaneous combination therapies with sunitinib.Co-corresponding Authors: ASB and JRCitation Format: Edward N. Rampersaud, Jonathan W. Said, Adrian Bot, Frederic D. Birkhauser, Nils Kroeger, Gang Zeng, Fairooz F. Kabbinavar, Antoni Ribas, Allan J. Pantuck, Arie S. Belldegrun, Joseph Riss. Efficacy and safety of the Ad-GM·CAIX dendritic cell-based vaccine in treating in vivo metastatic renal cell carcinoma compared to sunitinib monotherapy and simultaneous vaccine-sunitinib combination therapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2819. doi:10.1158/1538-7445.AM2014-2819 [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01826877&atom=%2Fcanres%2F74%2F19_Supplement%2F2819.atom" @default.
• W1508516210 created "2016-06-24" @default.
• W1508516210 creator A5006496749 @default.
• W1508516210 creator A5013867374 @default.
• W1508516210 creator A5034675508 @default.
• W1508516210 creator A5039495553 @default.
• W1508516210 creator A5060752508 @default.
• W1508516210 creator A5064185471 @default.
• W1508516210 creator A5069683592 @default.
• W1508516210 creator A5070232515 @default.
• W1508516210 creator A5083115147 @default.
• W1508516210 creator A5083745558 @default.
• W1508516210 creator A5087799211 @default.
• W1508516210 date "2014-09-30" @default.
• W1508516210 modified "2023-09-26" @default.
• W1508516210 title "Abstract 2819: Efficacy and safety of the Ad-GM·CAIX dendritic cell-based vaccine in treatingin vivometastatic renal cell carcinoma compared to sunitinib monotherapy and simultaneous vaccine-sunitinib combination therapy" @default.
• W1508516210 doi "https://doi.org/10.1158/1538-7445.am2014-2819" @default.
• W1508516210 hasPublicationYear "2014" @default.
• W1508516210 type Work @default.
• W1508516210 sameAs 1508516210 @default.
• W1508516210 citedByCount "0" @default.
• W1508516210 crossrefType "proceedings-article" @default.
• W1508516210 hasAuthorship W1508516210A5006496749 @default.
• W1508516210 hasAuthorship W1508516210A5013867374 @default.
• W1508516210 hasAuthorship W1508516210A5034675508 @default.
• W1508516210 hasAuthorship W1508516210A5039495553 @default.
• W1508516210 hasAuthorship W1508516210A5060752508 @default.
• W1508516210 hasAuthorship W1508516210A5064185471 @default.
• W1508516210 hasAuthorship W1508516210A5069683592 @default.
• W1508516210 hasAuthorship W1508516210A5070232515 @default.
• W1508516210 hasAuthorship W1508516210A5083115147 @default.
• W1508516210 hasAuthorship W1508516210A5083745558 @default.
• W1508516210 hasAuthorship W1508516210A5087799211 @default.
• W1508516210 hasConcept C121608353 @default.
• W1508516210 hasConcept C126322002 @default.
• W1508516210 hasConcept C143998085 @default.
• W1508516210 hasConcept C203014093 @default.
• W1508516210 hasConcept C22070199 @default.
• W1508516210 hasConcept C2776999253 @default.
• W1508516210 hasConcept C2777472916 @default.
• W1508516210 hasConcept C2777701055 @default.
• W1508516210 hasConcept C2779490328 @default.
• W1508516210 hasConcept C2908647359 @default.
• W1508516210 hasConcept C502942594 @default.
• W1508516210 hasConcept C71924100 @default.
• W1508516210 hasConcept C8891405 @default.
• W1508516210 hasConcept C99454951 @default.
• W1508516210 hasConceptScore W1508516210C121608353 @default.
• W1508516210 hasConceptScore W1508516210C126322002 @default.
• W1508516210 hasConceptScore W1508516210C143998085 @default.
• W1508516210 hasConceptScore W1508516210C203014093 @default.
• W1508516210 hasConceptScore W1508516210C22070199 @default.
• W1508516210 hasConceptScore W1508516210C2776999253 @default.
• W1508516210 hasConceptScore W1508516210C2777472916 @default.
• W1508516210 hasConceptScore W1508516210C2777701055 @default.
• W1508516210 hasConceptScore W1508516210C2779490328 @default.
• W1508516210 hasConceptScore W1508516210C2908647359 @default.
• W1508516210 hasConceptScore W1508516210C502942594 @default.
• W1508516210 hasConceptScore W1508516210C71924100 @default.
• W1508516210 hasConceptScore W1508516210C8891405 @default.
• W1508516210 hasConceptScore W1508516210C99454951 @default.
• W1508516210 hasLocation W15085162101 @default.
• W1508516210 hasOpenAccess W1508516210 @default.
• W1508516210 hasPrimaryLocation W15085162101 @default.
• W1508516210 hasRelatedWork W1889102163 @default.
• W1508516210 hasRelatedWork W1939976784 @default.
• W1508516210 hasRelatedWork W2077072111 @default.
• W1508516210 hasRelatedWork W2229363886 @default.
• W1508516210 hasRelatedWork W2275084659 @default.
• W1508516210 hasRelatedWork W2312562943 @default.
• W1508516210 hasRelatedWork W2317873860 @default.
• W1508516210 hasRelatedWork W2324938652 @default.
• W1508516210 hasRelatedWork W2365013012 @default.
• W1508516210 hasRelatedWork W2481243289 @default.
• W1508516210 hasRelatedWork W2483562035 @default.
• W1508516210 hasRelatedWork W2885613276 @default.
• W1508516210 hasRelatedWork W2886429192 @default.
• W1508516210 hasRelatedWork W2953545278 @default.
• W1508516210 hasRelatedWork W2955619780 @default.
• W1508516210 hasRelatedWork W2987335754 @default.
• W1508516210 hasRelatedWork W3035339338 @default.
• W1508516210 hasRelatedWork W3083125273 @default.
• W1508516210 hasRelatedWork W3083762900 @default.
• W1508516210 hasRelatedWork W3181040319 @default.
• W1508516210 isParatext "false" @default.
• W1508516210 isRetracted "false" @default.
• W1508516210 magId "1508516210" @default.
• W1508516210 workType "article" @default.